PMID: 11927282Apr 3, 2002Paper

STI571 (Gleevec) as a paradigm for cancer therapy

Trends in Molecular Medicine
Brian J Druker

Abstract

STI571 (Gleevec, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection and possible mechanisms of resistance to STI571. Finally, the potential use of STI571 with different tumors and the translation of this paradigm to other malignancies are explored.

References

Mar 15, 1990·Nature·N HeisterkampJ Groffen
Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M A KelliherN Rosenberg
Aug 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·O N WitteD Baltimore
Apr 11, 1984·Nucleic Acids Research·C S Tung, S C Harvey
Jan 13, 1998·Biochimica Et Biophysica Acta·K S Kolibaba, B J Druker
Jan 29, 1999·Journal of the National Cancer Institute·P le CoutreC Gambacorti-Passerini
Apr 29, 1999·The New England Journal of Medicine·C L Sawyers
Jul 31, 1999·Annals of Internal Medicine·S FaderlH M Kantarjian
Jan 5, 2000·The Journal of Clinical Investigation·B J Druker, N B Lydon
Mar 7, 2000·The American Journal of Pathology·M L LuxJ A Fletcher
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Sep 22, 2001·Science·C BartheJ R Mahon
Sep 25, 2001·Blood·J M Goldman, B J Druker
Sep 25, 2001·Science·A HochhausM D'Incalci

❮ Previous
Next ❯

Citations

Apr 30, 2013·Analytical and Bioanalytical Chemistry·Alicia D PowersSean P Palecek
Mar 20, 2004·Trends in Cardiovascular Medicine·Philippe Boucher, Michael Gotthardt
May 24, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J P A BaakE A M Janssen
Jan 28, 2003·Drug Discovery Today·Jeffrey S Ross, Geoffrey S Ginsburg
May 10, 2003·Trends in Immunology·Steven B Kanner, Juan J Perez-Villar
Jun 28, 2003·Trends in Molecular Medicine·Guy Makin, Caroline Dive
Jul 29, 2010·Parasitology·Nathalie WurtzDaniel Parzy
May 28, 2004·Nature·Robert L StrausbergGregory J Riggins
Jan 1, 2009·Nature Reviews. Drug Discovery·Véronique Baud, Michael Karin
Dec 21, 2002·Differentiation; Research in Biological Diversity·Joanne L YuR S Kerbel
Apr 9, 2004·The New England Journal of Medicine·Ching-Hon PuiJames R Downing
Jul 18, 2008·Proceedings of the National Academy of Sciences of the United States of America·Frank KuhnertCalvin J Kuo
Apr 23, 2009·Assay and Drug Development Technologies·Richard M Eglen, Terry Reisine
Jul 9, 2004·Journal of the National Cancer Institute·Giuditta CuccuruFranco Zunino
Aug 12, 2009·Current Opinion in Rheumatology·Joao A de Andrade, Victor J Thannickal
Jul 28, 2006·Cold Spring Harbor Symposia on Quantitative Biology·T F WestbrookS J Elledge
Oct 14, 2004·Annals of the Rheumatic Diseases·J J O'shea
May 3, 2003·The Journal of Clinical Investigation·Gabriele BergersDouglas Hanahan
Jul 29, 2010·The Journal of Clinical Investigation·Morassa Mohseni, Ben Ho Park
Jul 23, 2011·Genes & Cancer·Rónán C O'Hagan, Joerg Heyer
Jan 1, 2005·Hereditary Cancer in Clinical Practice·Lidia LarizzaPaola Riva
Nov 11, 2011·The Journal of Clinical Endocrinology and Metabolism·Xunqin YinJ Julie Kim
Apr 12, 2008·PLoS Computational Biology·Ali BashirBenjamin J Raphael
May 3, 2012·Proceedings of the American Thoracic Society·William Pao
Aug 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·William PaoHarold Varmus
Jun 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Alexis A BorisyCurtis T Keith
Mar 30, 2004·Proceedings of the National Academy of Sciences of the United States of America·Akrit SodhiJ Silvio Gutkind
Sep 24, 2004·Gynecologic Oncology·Brian M SlomovitzKaren H Lu
Sep 19, 2003·Wiener klinische Wochenschrift·Christian SillaberPeter Valent
Apr 4, 2015·Expert Opinion on Therapeutic Targets·Mahdi ShabaniFazel Shokri
Oct 24, 2007·Cancer Investigation·Jeffrey M Skolnik, Peter C Adamson
Oct 16, 2015·Microcirculation : the Official Journal of the Microcirculatory Society, Inc·William B StallcupFusanori Yotsumoto
Aug 1, 2008·Kidney International·Li LiAlfred K Cheung
Mar 5, 2016·Journal of Cancer Research and Clinical Oncology·Jonas Cicenas
Apr 28, 2009·Advanced Drug Delivery Reviews·Dominik E Dorer, Dirk M Nettelbeck

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved